Kodiak Sciences KOD 深 沪
已收盘 08-14 16:00:00 美东时间
41.35
+1.370
+3.43%
华盛通- 最 高42.00
- 今 开37.40
- 成交量 74.71万股
- 最 低 36.35
- 昨 收 39.98
- 总市值 25.88亿
- 52周最高 47.8417
- 市盈率 静 --
- 换手率 1.19%
- 52周最低 8.29
- 委 比 -18.52%
- 总股本 6257.84万
- 历史最高 171.21
- 量 比 1.35
- 振 幅 14.13%
- 历史最低 1.37
- 每 手 1
- 风险率 11.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kodiak Sciences Q2 EPS $(1.05) Misses $(0.95) Estimate
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.95) by 10.53 percent. This is a 1.94 percent decrease over losses of $(1.03) per share from the same period last year.
08-14 04:03
Kodiak Sciences Enrols First Patients In Global Phase 3 ALTO Trial Evaluating KSI-501 In Patients With Diabetic Macular Edema
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina-focused biotechnology company committed to researching, developing a...
08-11 04:45
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
JP Morgan Maintains Overweight on Kodiak Sciences, Raises Price Target to $66
JP Morgan analyst Anupam Rama maintains Kodiak Sciences (NASDAQ:KOD) with a Overweight and raises the price target from $56 to $66.
08-03 23:34
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises Inc (NASDAQ:APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Adjusted diluted earnings came in at 57 cents per share, topping the a...
06-26 22:18
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
Kymera Therapeutics announced the appointment of Felix J. Baker, PhD, as Chairman of the Board, succeeding Bruce Booth, DPhil, who will remain an Independent Director. Dr. Baker has been a strategic partner since 2024, contributing valuable insights as Kymera advances its pipeline and expands its growth. Dr. Baker, a Managing Member of Baker Brothers Investments, holds advanced degrees in Immunology from Stanford University and serves on multiple...
06-24 20:01
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Chardan Capital Upgrades Kodiak Sciences to Buy, Raises Price Target to $61
Chardan Capital analyst Daniil Gataulin upgrades Kodiak Sciences (NASDAQ:KOD) from Neutral to Buy and raises the price target from $14 to $61.
05-11 20:11
Kodiak Sciences' KSI-101 MESI Data From Tertiary Care Uveitis Practice Consistent With Phase 1b APEX Study Results
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued
05-01 14:35
